Cancer patients with septic shock: mortality predictors and neutropenia

Regazzoni, Carlos Javier; Irrazabal, Célica; Luna, Carlos M.; Poderoso, Juan José

doi:10.1007/s00520-004-0667-5

Cited by 56 publications

(34 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neutropenia was not found to affect mortality in cancer patients with Streptococcus pneumoniae bacteraemia [12], as well as bacteraemia caused by other micro-organisms [13]. In line with these data, five other studies evaluating patients hospitalised in ICU showed neutropenia to not be independently associated with mortality in cancer patients with different sites of infection [14][15][16][17][18]. During the past decades, the attention in management of infections in cancer patients has focused on fever and neutropenia [19].…”

Section: Discussionmentioning

confidence: 86%

The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia

et al. 2008

View full text Add to dashboard Cite

Although the presence of neutropenia may predispose cancer patients to develop community-acquired pneumonia, the role of neutropenia on their outcomes has not been investigated. The purpose of the present study was to compare clinical outcomes of cancer community-acquired pneumonia patients with and without neutropenia.Patients with cancer, identified in the Community-Acquired Pneumonia Organization database, were divided into two groups according to the type of cancer and the presence of neutropenia: patients with solid cancer without neutropenia versus those with functional or absolute neutropenia. Among the 3,106 community-acquired pneumonia patients enrolled, 135 had cancer without neutropenia and 75 had cancer with neutropenia.No significant difference was found between patients with and without neutropenia regarding mean time to clinical stability (5.4¡2.7 versus 4.9¡2.7 days, respectively), mean length of hospital stay (9.2¡7.7 versus 9.9¡9.6 days) and in-hospital mortality (18 versus 15%, respectively). Using a multiple logistic regression model, neutropenia was not associated with mortality in cancer patients when adjusting for significant covariates (odds ratio 1.30).Lack of neutropenia, during the initial evaluation of a cancer community-acquired pneumonia patient, should not be considered an indicator of better clinical outcome.

show abstract

Section: Discussionmentioning

confidence: 86%

The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Intheliterature,respiratoryfailure(41-45%)andsepsis(24-33%) were the main reasons for an ICU admission and the ICUmortalityrankedbetween30and69%inthesepatients [1][2][3]. Nevertheless, an ICU stay may bridge a transitory complication and thus donate lifetime even to patients with advancedmalignantdiseases.…”

Section: Introductionmentioning

confidence: 99%

Mortality of Patients with Hematological Malignancy after Admission to the Intensive Care Unit

Horster

Stemmler²,

Mandel³

et al. 2012

Onkologie

View full text Add to dashboard Cite

Background: The admission of patients with malignancies to an intensive care unit (ICU) still remains a matter of substantial controversy. The identification of factors that potentially influence the patient outcome can help ICU professionals make appropriate decisions. Patients and Methods: 90 adult patients with hematological malignancy (leukemia 47.8%, high-grade lymphoma 50%) admitted to the ICU were analyzed retrospectively in this single-center study considering numerous variables with regard to their influence on ICU and day-100 mortality. Results: The median simplified acute physiology score (SAPS) II at ICU admission was 55 (ICU survivors 47 vs. 60.5 for non-survivors). The overall ICU mortality rate was 45.6%. With multivariate regression analysis, patients admitted with sepsis and acute respiratory failure had a significantly increased ICU mortality (sepsis odds ratio (OR) 9.12, 95% confidence interval (CI) 1.1– 99.7, p = 0.04; respiratory failure OR 13.72, 95% CI 1.39–136.15, p = 0.025). Additional factors associated with an increased mortality were: high doses of catecholamines (ICU: OR 7.37, p = 0.005; day 100: hazard ratio (HR) 2.96, p < 0.0001), renal replacement therapy (day 100: HR 1.93, p = 0.026), and high SAPS II (ICU: HR 1.05, p = 0.038; day 100: HR 1.2, p = 0.027). Conclusion: The decision for or against ICU admission of patients with hematological diseases should become increasingly independent of the underlying malignant disease.

show abstract

“…In Brazil, Soares et al [18] reported a 44% of mortality rate in a cancer group admitted at ICU due to medical causes, not specifically to sepsis, which accounted only for 15% of admissions. Other authors such as Staudinger et al [27], Regazzoni et al [28], and Rosolem et al [29] reported an ICU mortality rate of 62%, 53.4%, and 51 % in septic patients with cancer admitted at the ICU, respectively.…”

Section: Discussionmentioning

confidence: 96%

sTREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock

Ravetti

Moura

Vieira³

et al. 2015

Journal of Critical Care

View full text Add to dashboard Cite

show abstract

Cancer patients with septic shock: mortality predictors and neutropenia

Abstract: Septic shock among cancer patients admitted to the ICU has a mortality rate similar to that reported for mixed populations, and it is particularly increased when hepatic or respiratory dysfunction develop. Neutropenia on admission does not seem to modify outcome.

Cited by 56 publications

References 29 publications

The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia

The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia

Mortality of Patients with Hematological Malignancy after Admission to the Intensive Care Unit

sTREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock

Contact Info

Product

Resources

About